Augustin Amour

Augustin Amour is a highly experienced scientific consultant with a robust background in drug discovery and development, currently serving at Kuano and Amour Scientific Consulting. With a notable tenure at GSK, Augustin led various immunology projects and was instrumental in transitioning pre-clinical data to clinical studies. As Co-Chair of the Treatment Recommendation Group for the PUMA Early Psychosis Platform Trial at the University of Oxford, Augustin emphasizes patient-centred approaches. Additional roles include guest editor for a special issue on AI applications in drug discovery and chair of the Biochemical Society’s Industrial Advisory Panel. Augustin holds a PhD in Enzymology from Paris-Sud University and has extensive academic and industry experience that informs a strategic approach to innovation in drug development.